Colette Owens
YOU?
Author Swipe
View article: Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era Open
View article: Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma Open
Not available.
View article: Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial Open
Patients with primary refractory or relapsed (R/R) MYC-driven aggressive B-cell lymphomas, such as Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), and double-hit lymphoma (DHL)/triple-hit lymphoma (THL), have a dismal prognosis with f…
View article: 858 | OPTIMIZING FRONTLINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA IN OLDER ADULTS: A GLOfitamab‐BASED, RESPONSE‐ADAPTED, WINDOW‐StYle STUDY (GLORY)
858 | OPTIMIZING FRONTLINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA IN OLDER ADULTS: A GLOfitamab‐BASED, RESPONSE‐ADAPTED, WINDOW‐StYle STUDY (GLORY) Open
View article: 183 | MUTATIONAL LANDSCAPE OF B‐CELL LYMPHOMAS: CLINICAL EVALUATION OF THE MSK‐ACCESS HEME CELL‐FREE DNA NEXT‐GENERATION SEQUENCING ASSAY
183 | MUTATIONAL LANDSCAPE OF B‐CELL LYMPHOMAS: CLINICAL EVALUATION OF THE MSK‐ACCESS HEME CELL‐FREE DNA NEXT‐GENERATION SEQUENCING ASSAY Open
View article: 27 | MOSUNETUZUMAB (MOSUN) PRODUCES DURABLE BENEFIT IN PATIENTS (PTS) WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA (FL): EXTENDED FOLLOW UP OF THE MITHIC‐FL1 TRIAL
27 | MOSUNETUZUMAB (MOSUN) PRODUCES DURABLE BENEFIT IN PATIENTS (PTS) WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA (FL): EXTENDED FOLLOW UP OF THE MITHIC‐FL1 TRIAL Open
View article: Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a <i>TP53</i> mutation
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a <i>TP53</i> mutation Open
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients with M…
View article: Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience Open
The combination of rituximab and lenalidomide (R-len) stands as an established treatment for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, the reproducibility of clinical trial results in routine clinical practic…
View article: <i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation Open
View article: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation Open
Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving…
View article: Retrospective characterization of nodal marginal zone lymphoma
Retrospective characterization of nodal marginal zone lymphoma Open
Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinica…
View article: PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin Lymphoma
PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin Lymphoma Open
Introduction: Interim PET is highly predictive of outcome for patients (pts) with stage III or IV Hodgkin lymphoma (HL) treated with 6 cycles of Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD). The RATHL study showed that PET-2 nega…
View article: PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA Open
Background: Outcomes of classical Hodgkin lymphoma (cHL) remain poor in older adults (OA) with 5- year progression free survival (PFS) of 60% even with curative therapy (Cheng, et al. Blood Advances 2022). In the ECHELON-1 study, brentuxim…
View article: <i>TP53</i>mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
<i>TP53</i>mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy Open
Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in progno…
View article: T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma Open
Figure 1: Progression-free survival for patients enrolled onto part I of the phase II study evaluating P-GVD followed by consideration for HDT/AHCT. 36 pts underwent HDT/AHCT. 2 pts declined transplant and were censored after 2 and 3 month…
View article: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates Open
PURPOSE To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non–clear-cell renal cell carcinoma (RCC). PATIENTS AND METHODS Patients had advanced non–clear-cell renal carcinoma who underwen…
View article: A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is molecularly dependent on B-cell receptor (BCR) signaling. 1The Bruton tyrosine kinase (BTK) inhibitor ibrutinib suppresses a key mediator of the BCR pathway, with response rates of 67% to 77% in patients with …
View article: Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma Open
Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults with suboptimal therapeutic outcomes due to increased treatment-related mortality and toxicities in vulnerable patients, clinically defined by geriatric impairments s…
View article: Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma Open
PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTria…
View article: PRELIMINARY ACTIVITY OF DEVIMISTAT (CPI 613) IN PATIENTS WITH RELAPSED OR REFRACTORY BURKITT LYMPHOMA/LEUKEMIA
PRELIMINARY ACTIVITY OF DEVIMISTAT (CPI 613) IN PATIENTS WITH RELAPSED OR REFRACTORY BURKITT LYMPHOMA/LEUKEMIA Open
Introduction: Patients (pts) with primary refractory or relapsed Burkitt lymphoma/leukemia (BL) or high-grade B-cell lymphoma with MYC and BCL2 rearrangements (double hit, DHL) and/or BCL6 (triple hit, THL) have a dismal prognosis. A dysre…
View article: Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies Open
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines of therapy based on data from sin…
View article: Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma Open
High-grade B-cell lymphoma (HGBL) with translocations involving MYC and BCL2 or BCL6 comprises ∼10% of cases of diffuse large B-cell lymphoma (DLBCL) and carries a poor prognosis. The incidence, prognosis, and optimal therapy for DLBCL har…
View article: Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma Open
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma that, like other Hodgkin lymphomas, has historically been treated aggressively. However, in most cases, NLPHL has an indolent course, which raises the qu…
View article: PET-Based Staging Reduces the Prognostic Impact of Early Disease Progression in Patients with Follicular Lymphoma
PET-Based Staging Reduces the Prognostic Impact of Early Disease Progression in Patients with Follicular Lymphoma Open